BHV-7000 for Bipolar Disorder
Recruiting at 32 trial locations
CM
LW
Overseen ByLouis Wagner
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2 & 3
Waitlist Available
Sponsor: Biohaven Therapeutics Ltd.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Eligibility Criteria
This trial is for adults aged 18-75 with a BMI of ≥18 and ≤35, diagnosed with bipolar disorder type I. They must have had at least one previous manic episode in the last two years and be hospitalized voluntarily for a current manic episode. Participants need to stop other psychotropic meds during screening.Inclusion Criteria
My manic episodes last no longer than 12 weeks.
Key
My BMI is between 18 and 35.
See 4 more
Treatment Details
Interventions
- BHV-7000 (Anti-epileptic agent)
Trial OverviewThe study tests if BHV-7000 is safe and effective for treating acute mania in bipolar disorder I patients compared to a placebo. It's designed to see how well it works when participants are experiencing an active manic episode.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: BHV-7000Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biohaven Therapeutics Ltd.
Lead Sponsor
Trials
13
Recruited
4,800+